Parkman Healthcare Partners

Parkman Healthcare Partners

Parkman Healthcare Partners operates from Greenwich with additional offices in Palo Alto, Boston, Stamford, New York, and Miami. The firm is 100% employee-owned, and its partnership includes three MDs alongside a CFO/CCO, a pattern that embeds clinical vetting directly into the investment process. The website positions the firm as driven by "intellectual curiosity" and an "evidence-based approach." The strategy concentrates on small- and mid-cap companies across five subsectors: biotech, pharma, medical devices and diagnostics, life science research tools, and healthcare services. The firm describes a dual mandate — thematic growth investing paired with systematic risk management — designed to capture value inflection points as standards of care evolve. The investment team is structured for deep fundamental research, and the partnership’s three physician-analysts (Matthew Ostrup, Seungyeon Jung, and Lindsay Edwards, each holding an MD) signal a commitment to clinical and scientific due diligence that goes beyond standard sell-side consensus. The firm lists no specific portfolio company names, fund vehicles, or co-investors on its public site. Parkman discloses a team of 12 professionals and reports over 100 years of combined healthcare investment experience across the partnership. The leadership structure is flat, with five named partners sharing management and investment responsibilities. Gregory Martinez serves as Managing Member and CIO. Michael Elgort holds four titles — Partner, COO, CFO, and CCO — an operational concentration typical of lean asset managers. The firm highlights recent team growth with three new analyst hires. In 2023, partner Matthew Ostrup spoke at a Penn Biotech Group event in Philadelphia, consistent with the firm’s academic-medical network cultivation. No AUM, fund, or discrete vehicle information is publicly disclosed. Parkman’s architecture is notable for its clinical density: three of the five partners are physicians, and two of the three recently hired analysts hold MDs. That MD-to-investor ratio is unusually high for a generalist healthcare fund and represents a structural bet that therapeutic-area expertise is the first-line sourcing and risk-control mechanism. The firm does not disclose whether it runs a single pool or multiple strategies, but the employee-ownership structure suggests permanent capital alignment without external parent-entity constraints.